| Literature DB >> 31234394 |
Mostafa Mabrouk1, Rajakumari Rajendran2, Islam E Soliman3, Mohamed M Ashour4, Hanan H Beherei5, Khairy M Tohamy6, Sabu Thomas7, Nandakumar Kalarikkal8, Gangasalam Arthanareeswaran9, Diganta B Das10.
Abstract
Pharmaceutical particulates and membranes possess promising prospects for delivering drugs and bioactive molecules with the potential to improve drug delivery strategies like sustained and controlled release. For example, inorganic-based nanoparticles such as silica-, titanium-, zirconia-, calcium-, and carbon-based nanomaterials with dimensions smaller than 100 nm have been extensively developed for biomedical applications. Furthermore, inorganic nanoparticles possess magnetic, optical, and electrical properties, which make them suitable for various therapeutic applications including targeting, diagnosis, and drug delivery. Their properties may also be tuned by controlling different parameters, e.g., particle size, shape, surface functionalization, and interactions among them. In a similar fashion, membranes have several functions which are useful in sensing, sorting, imaging, separating, and releasing bioactive or drug molecules. Engineered membranes have been developed for their usage in controlled drug delivery devices. The latest advancement in the technology is therefore made possible to regulate the physico-chemical properties of the membrane pores, which enables the control of drug delivery. The current review aims to highlight the role of both pharmaceutical particulates and membranes over the last fifteen years based on their preparation method, size, shape, surface functionalization, and drug delivery potential.Entities:
Keywords: bio-imaging; bioactive molecules; drug delivery systems; membranes; pharmaceutical particulates
Year: 2019 PMID: 31234394 PMCID: PMC6631283 DOI: 10.3390/pharmaceutics11060294
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
Figure 1A model design of an inorganic nanoparticle (NP) functionalized with biomolecules for biomedical applications [6]. Reproduced with copyright permission from Springer Nature, 2010.
Figure 2Structural overview of the article.
Figure 3Receptor-mediated endocytosis of CNTs. (1) Association of ligand conjugated drug-loaded CNTs with receptor; (2) endosomal internalization of conjugates, (3) drug release, and (4,5) receptor regeneration [28]. Reproduced with copyright permission from Elsevier, 2016.
Figure 4Tumor-localized DOX delivery with simultaneous photothermal ablation [29]. Reproduced with copyright permission from Elsevier, 2017. Legend: FA, folic acid; GO, graphic oxide; AuNPs, gold NPs.
Figure 5TEM images of mesoporous silica nanoparticle (MSNP) material recorded from the direction (a) parallel or (b) perpendicular to the long axis of the meso-channels [45]. Reproduced with copyright permission from Elsevier, 2008.
Inorganic nanocarriers for drug delivery.
| Inorganic Carrier | Drug Loaded | Purpose | References |
|---|---|---|---|
| CaP | Docetaxel | Breast, lung, and ovarian cancer. | [ |
| CaP, dopamine nanographene oxide (NGO) | Methotrexate | Anti-rheumatic drug, breast adenocarcinoma. | [ |
| Heparin/CaCo/CaP | Doxorubicin hydrochloride | Breast, lung, bladder, stomach, and ovarian cancer, and leukaemia. | [ |
| Porous silica CaP | 5-fluorouracil | Mammary tumors | [ |
| NGO | SN38 | Colon cancer | [ |
| Carboxylate NDs | Purvalanol and 4-hydroxytamoxitan | Liver and breast cancer | [ |
| Single-walled carbon nanotubes (SWNTs)-polyethylene glycol (PEG), NGO-PEG and MSNPs-GO-chitosan (CHI) | Doxorubicin | Leukaemia, breast cancer, gastric cancer, head and neck cancer, Hodgkin’s lymphoma, liver cancer, kidney cancer, ovarian cancer, small cell lung cancer, soft tissue sarcoma, thyroid cancer, bladder cancer, uterine sarcoma. | [ |
| NDs-NaCl | HT-29 colorectal cancer cells. | [ | |
| Gold NPs | Paclitaxel | Breast, lung, and pancreatic cancer. | [ |
Figure 6NPs used to repair a bone fracture: in cases of bone fracture, nanomaterials have been implanted into the target area (adapted from [62]).
Figure 7Scanning electron micrographs of L929 mouse fibroblasts growing on a multi-walled carbon nanotube (MWCNT)-based network [73]. Reproduced with copyright permission from the American Chemical Society, 2004.
Figure 8A semiconductor quantum and a quantum dot (QD) aqueous solution under UV light showing bright pink fluorescence. QDs are widely used in fluorescence imaging (adapted from [99]).
Figure 9A single-walled carbon nanotube and an aqueous solution of SWNTs functionalized by PEG-SWNTs with highly optical properties, which are considered excellent platforms for biomedical imaging [99]. Reproduced with copyright permission from Springer Nature, 2010.
Figure 10Key characteristics of porous membranes.
Various formulations of drug delivery systems emphasizing the physico-chemical and mechanical properties of various polymers being used in commercially available membrane drug delivery systems.
| Polymers | Structure | Fabrication Method | Commercial Products/Literatures | Comments | Reference |
|---|---|---|---|---|---|
| Polycarbonate (PC) |
| Ion-track etching | Estrogen | Excellent stability against oxidation and biodegradation and improves antifouling properties | [ |
| Polyethylene (PE) |
| Ion-track etching | Catapress (Clonidine), Boehringer IngelheimClimara (Estradiol), Berlex | Physico-chemical stability andordered pore formation with superior membrane performance | [ |
| Polyethylene terephthalate (PET) |
| Lithography | Ketoprofen | Biostable, antifouling, has better performance of membranes, in useful in preparing surgical meshes and ligaments | [ |
| Polystyrene (PS) |
| Lithography | d-limonene, ibuprofen | Chemical resistance, easy processing, lower cost, exhibits enhancements in strength, stiffness, toughness, and ductility | [ |
| PC, PE | - | Ion-track etching | Estraderm (Nitroglycerin), Rotta Research | Cost-effective and biocompatibility is fairly good | [ |
| PC, PE, PET, PS | - | Phase separation | Deponit (Nitroglycerin), Pharma SchwarzHabitrol (Nicotine), Novartis | Cost-effective and biocompatibility is fairly good | [ |
| Polyurethane (PU) |
| Sol-gel/solvent casting | Vivelle (Estradiol), Novartis | Good elasticity, biodegradable, suitable for hydrophilic drugs, biocompatibility is fairly good | [ |
| Polysiloxane (silicone) |
| Sol-gel/solvent casting | Prostep (Nicotine), Lederle, Transderm Nitro (Nitroglycerin), AlzaSyncro-Mate-C (Norgestomet) | Better insulation, excellent biocompatibility, and fabricated easily for hydrophilic drugs | [ |
| Polyisobutylene (PIB) |
| Solvent casting | Aminopyrene, Mitsubishi Petrochem Co., Japan | Good adhesive drug impermeable layer and high degree of tack or self-adhesion | [ |
| Polymethyl methacrylate (PMMA), poly (2-hydroxy ethyl methacrylate) |
| Layer by layer deposition | Androderm (Testosterone), SmithKline Beecham | Physical strength and transparency | [ |
| Polyvinyl alcohol (PVA), Poly (ethylene-co-vinyl acetate) |
| Solvent casting | Nitro-Dur I (Nitroglycerin), Key PharmaTestoderm TTS (Testosterone), Alza | Rate-controlling membranes, high membrane permeability, hydrophilicity and strength, suitable for lipophilic drugs | [ |
| Polyacrylic acid, polyacrylate, polyacrylamide |
| Layer by layer deposition | Epinitril (Nitroglycerin), Rotta ResearchMonsanto (Fentanyl), Dow Corning | Good adhesivity and spreadability and contains a drug impermeable layer | [ |
| Polylactides (PLA), polylactic-co-glycolic acid (PLGA), polyglycolides (PGA) | Sol-gel/solvent casting | Propranalol, Exxon Chemical Co. | Good biocompatibility; lactic and glycolic acids are the degradation products and they are easily eliminated from the body | [ | |
| Polyvinyl pyrrolidone (PVP), poly (N-vinyl pyrrolidone) |
| Sol-gel/solvent casting | Cytarabine, ara-ADA, Polyscience | Superior biocompatibility, has suspension capabilities, antinucleating agent, and enhances release rate | [ |
| Polyethylene glycol (PEG) | Sol-gel/solvent casting | Miconozale, Rohm, Germany | Chemically inert and free of leachable impurities | [ | |
| Oxide plus polymer | - | Sol-gel/solvent casting | Superior biocompatibility and has narrow pore size | ||
| Polymer coating on support membrane | - | Layer by layer deposition | [ |
Figure 11Polymeric membrane used for drug delivery system.
Figure 12Classification of polymeric membranes for drug delivery.
Figure 13Diagrammatic representation of membrane permeation-controlled system in which the drug reservoir is sandwiched between the membrane layers and the adhesive layers facing the skin’s surface (adapted from [134]).
Figure 14Ocusert: (1) and (4) show transparent polymer membranes, (2) shows a titanium dioxide white ring, and (3) shows a pilocarpine core reservoir (adapted from [136]).
Figure 15Progestasert IUD with structural components shown (adapted from [137]).
Figure 16A polymer matrix diffusion-controlled system.
Figure 17Nitro-Dur system (adapted from [140]).
Figure 18Compudose implant.